Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Novel therapies for memory cells in autoimmune diseases.
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
4-aminopyridine toxicity: a case report and review of the literature.
Neuroprotective effect of masitinib in rats with postischemic stroke.
Environmental risk factors for multiple sclerosis. Part I: the role of infection.
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
Idebenone for primary progressive multiple sclerosis
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Balance impairment in people with multiple sclerosis: Preliminary evidence for the Balance Evaluation Systems Test.
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.
Sanofi MS drug nears green light after pass-the-parcel marathon
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
Extoxnet (extension toxicology network), 4-aminopyridine

Pages